Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Syros Pharmaceuticals Inc SYRS

Healthcare Biotechnology
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. The Company is advancing Tamibarotene, a selective retinoic acid receptor alpha (RARa), agonist for which the Company is conducting SELECT-MDS-1, a Phase III clinical trial evaluating tamibarotene in... see more

Recent & Breaking News (NDAQ:SYRS)

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire November 4, 2022

Syros Pharmaceuticals to Present Initial Data from SELECT-AML-1 Phase 2 Trial at 64th ASH Annual Meeting

Business Wire November 3, 2022

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire October 5, 2022

Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement

Business Wire September 16, 2022

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Syros Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

PR Newswire September 15, 2022

Syros and Tyme Technologies Announce Stockholder Approval of Merger

Business Wire September 15, 2022

Syros Receives FDA Orphan Drug Designation for SY-5609 for the Treatment of Pancreatic Cancer

Business Wire September 13, 2022

Syros to Present at H.C. Wainwright 24th Annual Global Investment Conference

Business Wire September 7, 2022

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire September 2, 2022

Syros Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

Business Wire August 9, 2022

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire August 4, 2022

Syros Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS

Business Wire August 3, 2022

Syros to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022

Business Wire August 2, 2022

TYME TECHNOLOGIES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TYME Technologies, Inc. - TYME

PR Newswire July 27, 2022

SHAREHOLDER ALERT: Weiss Law Reminds SYRS, CNVY, RADA, and SIMO Shareholders About Its Ongoing Investigations

PR Newswire July 20, 2022

INVESTIGATION NOTICE: Halper Sadeh LLP Investigates RFP, LJPC, FSI, SYRS

PR Newswire July 12, 2022

SHAREHOLDER ALERT: Weiss Law Reminds SYRS, CNVY, RADA, and SIMO Shareholders About Its Ongoing Investigations

PR Newswire July 11, 2022

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Tyme Technologies, Inc. Merger

Newsfile July 6, 2022

INVESTIGATION NOTICE: Halper Sadeh LLP Investigates ELSE, STCN, SYRS

PR Newswire July 6, 2022

SHAREHOLDER ALERT: Weiss Law Investigates Syros Pharmaceuticals, Inc.

PR Newswire July 5, 2022